AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27623769 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher site enrollment (>60 patients/site)
Number of subjects: 7141
Study 27623769 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher site enrollment
Number of subjects: 7141
Study 24879143 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with energized dissection (ED)
Number of subjects: 745
Study 24879143 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with cold dissection (CD)
Number of subjects: 745
Study 22180393 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention
Number of subjects: 31
Study 22180393 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 31
Study 19329014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 48
Study 19329014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 48
Study 19329014 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 20089009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (4.6 mg/24 hr)
Number of subjects: 592
Study 20089009 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules (3-12 mg/day)
Number of subjects: 592
Study 15549297 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 77
Study 11862364 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 36
Study 11862364 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 36
Study 11862364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9857272 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program (CR+) for 2 months including an extensive educational program on cardiovascular risk factors, lipids, and diet
Number of subjects: 52
Study 9857272 — intervention group
Group type: COMPARATOR
Intervention: No cardiac rehabilitation (CR-)
Number of subjects: 52
Study 7712618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3337027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine serum albumin
Number of subjects: 0
Study 3337027 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef meat
Number of subjects: 0
Study 3337027 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white
Number of subjects: 0
Study 29671041 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (0.12% oropharyngeal rinse and 4% nasopharyngeal soap)
Number of subjects: 450
Study 29671041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 27687394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with f=9 beats per minute, VT=8 mL/kg, I:E=1:2.0
Number of subjects: 27
Study 27687394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with different combinations of f, VT, and I:E
Number of subjects: 27
Study 27687394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with changes in f, VT, and I:E
Number of subjects: 27
Study 27687394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with selected respiratory parameters
Number of subjects: 27
Study 24117808 — intervention group
Group type: COMPARATOR
Intervention: Complementary foods from 4 months of age (CF)
Number of subjects: 119
Study 24117808 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months (EBF)
Number of subjects: 119
Study 22858430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous landiolol at 5 μg/kg/min for 3 days (group L)
Number of subjects: 105
Study 22858430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisoprolol postoperatively with landiolol (group LB)
Number of subjects: 105
Study 22858430 — intervention group
Group type: COMPARATOR
Intervention: Control group without beta-blocker therapy (group C)
Number of subjects: 105
Study 22858430 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 105
Study 20532141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (IVBI) 1.25 mg/0.05 mL
Number of subjects: 24
Study 20532141 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 24
Study 18681757 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (N = 42)
Number of subjects: 80
Study 18681757 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (N = 38)
Number of subjects: 80
Study 18681757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 80
Study 15705599 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with beta‐carotene, vitamins C and E along with zinc (ACEZn) for 6 months
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of vitamin E
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of retinol
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of folic acid
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of nicotinic acid (preformed)
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of calcium
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of riboflavin
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of pantothenic acid
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of intake of biotin
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Mid‐tertile beta‐carotene intake
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of beta‐carotene intake (>6400 microg/day)
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Increased calcium intake
Number of subjects: 190
Study 15705599 — intervention group
Group type: COMPARATOR
Intervention: Increased riboflavin intake
Number of subjects: 190
Study 12585582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberdeen Colles' fracture brace
Number of subjects: 339
Study 12585582 — intervention group
Group type: COMPARATOR
Intervention: Conventional Colles' plaster cast
Number of subjects: 339
Study 10388248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg/kg/h
Number of subjects: 24
Study 10388248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5 mg/kg/h
Number of subjects: 24
Study 10388248 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 24
Study 8739822 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate (250 mg)
Number of subjects: 10
Study 8739822 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine hydrochloride (100 mg) with quinidine
Number of subjects: 10
Study 8739822 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine hydrochloride (100 mg) without quinidine (control)
Number of subjects: 10
Study 2070143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder irrigation
Number of subjects: 34
Study 2070143 — intervention group
Group type: COMPARATOR
Intervention: No bladder irrigation
Number of subjects: 34
Study 6129367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate administered during a 2.5 MJ (600 kcal) diet with 34 g protein and total fast (water and vitamins only) on alternate days for 21 days
Number of subjects: 0
Study 6129367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate administered during therapeutic starvation for 14 days
Number of subjects: 0
Study 6129367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate
Number of subjects: 0
Study 31525069 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced LVEF (<50%)
Number of subjects: 2991
Study 31525069 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF as continuous variable
Number of subjects: 2991
Study 29221978 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 44
Study 29221978 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solutions
Number of subjects: 44
Study 27603788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib therapy
Number of subjects: 275
Study 24471663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 2 g
Number of subjects: 240
Study 24471663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg
Number of subjects: 240
Study 24471663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous paracetamol 2 g and intravenous parecoxib 40 mg
Number of subjects: 240
Study 24471663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 22937736 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (22.5 mg/kg twice daily) with placebo‐azithromycin
Number of subjects: 189
Study 22937736 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg daily) with placebo‐amoxicillin‐clavulanic acid
Number of subjects: 189
Study 22937736 — intervention group
Group type: COMPARATOR
Intervention: Placebo‐azithromycin with placebo‐amoxicillin‐clavulanic acid
Number of subjects: 189
Study 22937736 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 189
Study 19895619 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for major depression over 18 months
Number of subjects: 149
Study 19895619 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for major depression
Number of subjects: 149
Study 18093298 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement therapy (PMT) given three times a week for four weeks.
Number of subjects: 0
Study 18093298 — intervention group
Group type: COMPARATOR
Intervention: Usual care without PMT
Number of subjects: 0
Study 16253086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) spray
Number of subjects: 51
Study 16253086 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (B‐HCl) spray
Number of subjects: 51
Study 16253086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus Benzydamine hydrochloride (CHX/B‐HCl) spray
Number of subjects: 51
Study 11344426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection balloon
Number of subjects: 322
Study 11344426 — intervention group
Group type: COMPARATOR
Intervention: No dissection balloon
Number of subjects: 322
Study 9701431 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) with Aerochamber
Number of subjects: 20
Study 9701431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebulizer
Number of subjects: 20
Study 9701431 — intervention group
Group type: COMPARATOR
Intervention: Jet Nebulizers
Number of subjects: 20
Study 9701431 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with Aerochamber
Number of subjects: 20
Study 8026055 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive postlytic strategy
Number of subjects: 3339
Study 8026055 — intervention group
Group type: COMPARATOR
Intervention: Conservative postlytic strategy
Number of subjects: 3339
Study 2767766 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 0.2 g with 300 ml of fresh milk
Number of subjects: 9
Study 2767766 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 0.2 g with 300 ml of water
Number of subjects: 9
Study 48832 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme aimed at instructing about hypertension and its treatment
Number of subjects: 230
Study 48832 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up with family doctors outside working-hours
Number of subjects: 230
Study 48832 — intervention group
Group type: COMPARATOR
Intervention: Follow-up with industrial physicians during work shifts
Number of subjects: 230
Study 31786721 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 1% Ascophyllum nodosum algae extract (AN1)
Number of subjects: 24
Study 31786721 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 2% Ascophyllum nodosum algae extract (AN2)
Number of subjects: 24
Study 31786721 — intervention group
Group type: COMPARATOR
Intervention: Control diet (AN0)
Number of subjects: 24
Study 28797188 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Symptoms and Signs Diary (PSSD)
Number of subjects: 0
Study 27875291 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Number of subjects: 134
Study 25533966 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3(‐) supplementation (12.9 mmol of NO3‐rich beetroot juice)
Number of subjects: 17
Study 23044089 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment
Number of subjects: 0
Study 22103578 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit goal primes followed by achievement threats
Number of subjects: 444
Study 22103578 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit goal primes followed by relationship threats
Number of subjects: 444
Study 22103578 — intervention group
Group type: COMPARATOR
Intervention: Opportunity to attribute anxiety to a mundane source
Number of subjects: 444
Study 19723679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-juven progesterone cream, 20 mg twice daily
Number of subjects: 131
Study 19723679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 17784896 — intervention group
Group type: EXPERIMENTAL
Intervention: Unobserved dosing of buprenorphine-naloxone for 3 months
Number of subjects: 119
Study 17784896 — intervention group
Group type: COMPARATOR
Intervention: Observed dosing of buprenorphine-naloxone for 3 months
Number of subjects: 119
Study 17784896 — intervention group
Group type: EXPERIMENTAL
Intervention: Unobserved dosing of buprenorphine-naloxone
Number of subjects: 119
Study 17784896 — intervention group
Group type: COMPARATOR
Intervention: Observed dosing of buprenorphine-naloxone
Number of subjects: 119
Study 15569116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria-fermented milk (100 mL/day for 12 weeks)
Number of subjects: 20
Study 15569116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11737814 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glycerine
Number of subjects: 109
Study 11737814 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% urea (combined with 4% sodium chloride)
Number of subjects: 109
Study 11737814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9189307 — intervention group
Group type: EXPERIMENTAL
Intervention: T75 (75% VO2max)
Number of subjects: 8
Study 9189307 — intervention group
Group type: COMPARATOR
Intervention: T55 (55% VO2max)
Number of subjects: 8
Study 8130541 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality scoring method
Number of subjects: 19
Study 3107115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (loading dose: 3 mg/kg body weight in 10 min; maintenance dose: 1 mg/kg in 20 min)
Number of subjects: 40
Study 3107115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide infusion (750 mg in 30 min)
Number of subjects: 40
Study 3107115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide orally (400 to 2,400 mg per day)
Number of subjects: 40
Study 3107115 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 31735121 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support (Cash Transfer schemes)
Number of subjects: 0
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 18113
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 18113
Study 29044861 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 18113
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBIT score
Number of subjects: 18113
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIA score
Number of subjects: 18113
Study 29044861 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMORR2 HAGES score
Number of subjects: 18113
Study 26519007 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41
Study 25115201 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Electronic Vision Enhancement System (p-EVES)
Number of subjects: 100
Study 25115201 — intervention group
Group type: COMPARATOR
Intervention: Conventional optical low vision aids (LVAs)
Number of subjects: 100
Study 22375577 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered physical activity and dietary behavior change intervention
Number of subjects: 0
Study 18644587 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiomatic phrasal verbs
Number of subjects: 0
Study 18644587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonidiomatic phrasal verbs
Number of subjects: 0
Study 17822464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation (PNS)
Number of subjects: 22
Study 17822464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 22
Study 16194311 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120
Study 16194311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine) (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120
Study 12668699 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day)
Number of subjects: 6632
Study 12668699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study 10531848 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes education intervention
Number of subjects: 0
Study 8705743 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser iridotomy
Number of subjects: 17
Study 8705743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential argon laser and Nd:YAG laser iridotomy
Number of subjects: 17
Study 1679736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with a liquid oligopeptide diet (n = 55)
Number of subjects: 107
Study 1679736 — intervention group
Group type: COMPARATOR
Intervention: Combination of 6‐methylprednisolone (48 mg daily, tapered) and sulfasalazine (3 g daily) (n = 52)
Number of subjects: 107
Study 6134042 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromocriptine (1.25 mg)
Number of subjects: 8
Study 6134042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3542346 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of moxalactam 2 g intramuscularly
Number of subjects: 78
Study 3542346 — intervention group
Group type: COMPARATOR
Intervention: Three-dose regimen of cefoxitin (2 g intramuscularly on call, followed by 2 g intravenously every six hours for two additional doses)
Number of subjects: 78
Study 28481758 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents (BOQ11-18)
Number of subjects: 501
Study 28481758 — intervention group
Group type: COMPARATOR
Intervention: Young Adults (YABOQ 18-30)
Number of subjects: 501
Study 28393570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 128
Study 28393570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 25774090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil target-controlled infusion (TCI) at 0.1682 ng/ml
Number of subjects: 60
Study 25774090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil target-controlled infusion (TCI) at various concentrations (0.19, 0.1809, 0.1723, 0.1641, 0.1563, 0.1489 ng/ml)
Number of subjects: 60
Study 23062248 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (twice-daily for 4 weeks by licensed massage therapists)
Number of subjects: 44
Study 23062248 — intervention group
Group type: COMPARATOR
Intervention: Control care (twice-daily for 4 weeks)
Number of subjects: 44
Study 20628648 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-moving events
Number of subjects: 0
Study 20628648 — intervention group
Group type: COMPARATOR
Intervention: Right-moving events
Number of subjects: 0
Study 18258511 — intervention group
Group type: EXPERIMENTAL
Intervention: SHOP-89 (1989-1993)
Number of subjects: 673
Study 18258511 — intervention group
Group type: EXPERIMENTAL
Intervention: SHOP-94 (1994-1998)
Number of subjects: 673
Study 16613928 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. acetaminophen 15 mg kg(‐1)
Number of subjects: 80
Study 16613928 — intervention group
Group type: COMPARATOR
Intervention: i.m. meperidine 1 mg kg(‐1)
Number of subjects: 80
Study 14526483 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers exposed to metallic mercury vapours
Number of subjects: 20
Study 14526483 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 10933330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 97
Study 10933330 — intervention group
Group type: COMPARATOR
Intervention: Oral propafenone
Number of subjects: 97
Study 8625373 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks
Number of subjects: 108
Study 8625373 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks + oral collagen hydrolysate, 10 g per day for 24 weeks
Number of subjects: 108
Study 8625373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral collagen hydrolysate, 10 g per day for 24 weeks (after calcitonin treatment)
Number of subjects: 108
Study 1351547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h)
Number of subjects: 2316
Study 1351547 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 2316
Study 1351547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2316